Overcoming Barriers to Biosimilar Adoption: Commentary on "Cost to Medicare of Delayed Adalimumab Biosimilar Availability"

Biosimilars hold the promise of reducing costs and improving access to costly biologic therapies, but barriers to biosimilars' development, entry, and uptake have resulted in limited savings so far, as demonstrated in an article published recently in this journal. As additional biologics, including Humira (adalimumab), lose their exclusivity over the next several years, addressing these barriers will be critical for reaching the market share and price reductions described by the authors and realizing biosimilars' savings potential.